According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.